Positive impacts of important bird and biodiversity areas on wintering waterbirds under changing temperatures throughout Europe and North Africa

Migratory waterbirds require an effectively conserved cohesive network of wetland areas throughout their range and life-cycle. Under rapid climate change, protected area (PA) networks need to be able to accommodate climate-driven range shifts in wildlife if they are to continue to be effective in the future. Thus, we investigated geographical variation in the relationship between local temperature anomaly and the abundance of 61 waterbird species during the wintering season across Europe and North Africa during 1990-2015. We also compared the spatio-temporal effects on abundance of sites designated as PAs, Important Bird and Biodiversity Areas (IBAs), both, or neither designation (Unlisted). Waterbird abundance was positively correlated with temperature anomaly, with this pattern being strongest towards north and east Europe. Waterbird abundance was higher inside IBAs, whether they were legally protected or not. Trends in waterbird abundance were also consistently more positive inside both protected and unprotected IBAs across the whole study region, and were positive in Unlisted wetlands in southwestern Europe and North Africa. These results suggest that IBAs are important sites for wintering waterbirds, but also that populations are shifting to unprotected wetlands (some of which are IBAs). Such IBAs may therefore represent robust candidate sites to expand the network of legally protected wetlands under climate change in north-eastern Europe. These results underscore the need for monitoring to understand how the effectiveness of site networks is changing under climate change.Peer reviewe

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

Background: Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse cardiovascular events (MACE) in people with overweight or obesity, but the effects of this drug on outcomes in patients with atherosclerotic cardiovascular disease and heart failure are unknown. We report a prespecified analysis of the effect of once-weekly subcutaneous semaglutide 2·4 mg on ischaemic and heart failure cardiovascular outcomes. We aimed to investigate if semaglutide was beneficial in patients with atherosclerotic cardiovascular disease with a history of heart failure compared with placebo; if there was a difference in outcome in patients designated as having heart failure with preserved ejection fraction compared with heart failure with reduced ejection fraction; and if the efficacy and safety of semaglutide in patients with heart failure was related to baseline characteristics or subtype of heart failure. Methods: The SELECT trial was a randomised, double-blind, multicentre, placebo-controlled, event-driven phase 3 trial in 41 countries. Adults aged 45 years and older, with a BMI of 27 kg/m2 or greater and established cardiovascular disease were eligible for the study. Patients were randomly assigned (1:1) with a block size of four using an interactive web response system in a double-blind manner to escalating doses of once-weekly subcutaneous semaglutide over 16 weeks to a target dose of 2·4 mg, or placebo. In a prespecified analysis, we examined the effect of semaglutide compared with placebo in patients with and without a history of heart failure at enrolment, subclassified as heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, or unclassified heart failure. Endpoints comprised MACE (a composite of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death); a composite heart failure outcome (cardiovascular death or hospitalisation or urgent hospital visit for heart failure); cardiovascular death; and all-cause death. The study is registered with ClinicalTrials.gov, NCT03574597. Findings: Between Oct 31, 2018, and March 31, 2021, 17 604 patients with a mean age of 61·6 years (SD 8·9) and a mean BMI of 33·4 kg/m2 (5·0) were randomly assigned to receive semaglutide (8803 [50·0%] patients) or placebo (8801 [50·0%] patients). 4286 (24·3%) of 17 604 patients had a history of investigator-defined heart failure at enrolment: 2273 (53·0%) of 4286 patients had heart failure with preserved ejection fraction, 1347 (31·4%) had heart failure with reduced ejection fraction, and 666 (15·5%) had unclassified heart failure. Baseline characteristics were similar between patients with and without heart failure. Patients with heart failure had a higher incidence of clinical events. Semaglutide improved all outcome measures in patients with heart failure at random assignment compared with those without heart failure (hazard ratio [HR] 0·72, 95% CI 0·60-0·87 for MACE; 0·79, 0·64-0·98 for the heart failure composite endpoint; 0·76, 0·59-0·97 for cardiovascular death; and 0·81, 0·66-1·00 for all-cause death; all pinteraction>0·19). Treatment with semaglutide resulted in improved outcomes in both the heart failure with reduced ejection fraction (HR 0·65, 95% CI 0·49-0·87 for MACE; 0·79, 0·58-1·08 for the composite heart failure endpoint) and heart failure with preserved ejection fraction groups (0·69, 0·51-0·91 for MACE; 0·75, 0·52-1·07 for the composite heart failure endpoint), although patients with heart failure with reduced ejection fraction had higher absolute event rates than those with heart failure with preserved ejection fraction. For MACE and the heart failure composite, there were no significant differences in benefits across baseline age, sex, BMI, New York Heart Association status, and diuretic use. Serious adverse events were less frequent with semaglutide versus placebo, regardless of heart failure subtype. Interpretation: In patients with atherosclerotic cardiovascular diease and overweight or obesity, treatment with semaglutide 2·4 mg reduced MACE and composite heart failure endpoints compared with placebo in those with and without clinical heart failure, regardless of heart failure subtype. Our findings could facilitate prescribing and result in improved clinical outcomes for this patient group. Funding: Novo Nordisk

Measurement of the very rare K+→π+ννˉK^+ \to \pi^+ \nu \bar\nu decay

The decay K+→π+νν¯ , with a very precisely predicted branching ratio of less than 10−10 , is among the best processes to reveal indirect effects of new physics. The NA62 experiment at CERN SPS is designed to study the K+→π+νν¯ decay and to measure its branching ratio using a decay-in-flight technique. NA62 took data in 2016, 2017 and 2018, reaching the sensitivity of the Standard Model for the K+→π+νν¯ decay by the analysis of the 2016 and 2017 data, and providing the most precise measurement of the branching ratio to date by the analysis of the 2018 data. This measurement is also used to set limits on BR(K+→π+X ), where X is a scalar or pseudo-scalar particle. The final result of the BR(K+→π+νν¯ ) measurement and its interpretation in terms of the K+→π+X decay from the analysis of the full 2016-2018 data set is presented, and future plans and prospects are reviewed

Study of the use of alternative energy sources in inland waterway transport

A study has been conducted on the use of alternative energy sources for propulsion of a vessel in inland waterway transport. It is clear that at this stage it is most appropriate to use a vessel designed for short-haul trips between two banks of a ferryboat for passengers and luggage or for recreation and entertainment. On this basis, research has been conducted on a newly designed and built vessel to carry up to 12 people. The drive is fully powered by 180-Ah batteries at 48 V. The batteries are charged by the sun through 5-kW solar panels. The results show that the vessel powered by two 5-kW electric motors can sail autonomously for about 1.5 hours, to travel about 13 km, at an average speed of 7.9 km/h with an average energy consumption of 71.3 kWh/100km when sailing on a linearly reversible route including sailing downstream and upstream on the Danube River

Multi-Force Bio-Active™ Archwires and Various Contemporary NiTi Multi-Force Archwires: Properties and Characteristics—A Review

The manufacturing of orthodontic archwires made from NiTi alloy has undergone numerous changes from the second half of the last century to modern times. Initially, superelastic-active austenitic NiTi alloys were predominant, followed by thermodynamic-active martensitic NiTi alloys, and, finally, the most recent development was graded thermodynamic alloys. These advancements have been the subject of extensive investigation in numerous studies, as they necessitated a deeper understanding of their properties. Furthermore, it is imperative that we validate the information provided by manufacturers regarding these archwires through independent studies. This review evaluates existing studies on the subject with a specific focus on the Bio-active multi-force NiTi archwire, by examining its mechanical, thermal, and physicochemical properties before and after clinical use. This archwire consists primarily of Ni and Ti, with traces of Fe and Cr, which release graduated, biologically tolerable forces which increase in a front-to-back direction and are affected by the temperature of the environment they are in. The review provides information to practicing orthodontists, facilitating informed decisions regarding the selection and use of Bio-active™ archwires for individual patient treatments

Effects of Clinical Use on the Mechanical Properties of Bio-Active^® (BA) and TriTanium^® (TR) Multiforce Nickel-Titanium Orthodontic Archwires

Multiforce orthodontic archwires are thermodynamic wires made of nickel-titanium alloy (Ni-Ti). They release biologically tolerable forces along their length, progressively increasing from front to back. The frontal archwires’ segments distribute the weakest force: the premolar, the greater, and the molar, the greatest. The aim of the present study was to determine the influence of clinical use on the mechanical properties of two types of multi-force orthodontic archwires (TriTanium®, American orthodontics; Bio-Active®, GC) with dimensions of 0.016 × 0.022 inches for periods of up to 8 weeks and over 8 weeks of in-vivo use. A three-point bending test was used, and the data gained is statistically analyzed through a multi-variance comparison Mann-Whitney test. We found that after uses of up to 8 weeks and over 8 weeks, the shape memory effect and superelasticity are preserved, as well as the tendency for differential force release along the length of the archwires is kept

Distribution of the Macrophyte Communities in the Danube Reflects River Serial Discontinuity

The Danube is the second-longest river in Europe that is subjected to various man-made alterations, including those related to hydro-power plants. We surveyed and analyzed the presence and abundance of macrophytes in the main channel from 2582 river kilometers (rkm) to 171 rkm. We also assessed selected habitat parameters in the sampled river stretches. Sixty-eight different plant species were recorded along the entire course. Among neophytes, we found Elodea nuttallii, E. canadensis, Vallisneriaspiralis and Azolla filiculoides. Based on similarity analysis, we distinguished 15 plant communities, most of which were defined as associations, which were classified into 5 alliances and represented three vegetation classes, namely vegetation of rooted hydrophytes Potamogetonetea, the vegetation of pleustophytes Lemnetea and vegetation of marshes Phragmitetea. The number and abundance of plant species, as well as plant communities recorded in single stretches, varied along the course. Canonical correspondence analysis (CCA) revealed that environmental parameters explained 21% of plant species composition. CCA runs with neophytes explained 41% of the variance, and current velocity, water transparency, species number and bank structure were significant variables. The present study revealed that the free-running sections of the river are poor in number and abundance of plant species, whereas impounded reaches mainly show an opposite result

WG3: New Concepts and Standards for Data management (Content, curation, quality management, technical framework, documentation)

MOBILISE WG3 WIK